AU2016339035A1 - Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors - Google Patents
Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors Download PDFInfo
- Publication number
- AU2016339035A1 AU2016339035A1 AU2016339035A AU2016339035A AU2016339035A1 AU 2016339035 A1 AU2016339035 A1 AU 2016339035A1 AU 2016339035 A AU2016339035 A AU 2016339035A AU 2016339035 A AU2016339035 A AU 2016339035A AU 2016339035 A1 AU2016339035 A1 AU 2016339035A1
- Authority
- AU
- Australia
- Prior art keywords
- neoepitopes
- hla
- matched
- patient
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 84
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 53
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 6
- 230000035945 sensitivity Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 168
- 238000011282 treatment Methods 0.000 claims abstract description 51
- 230000004044 response Effects 0.000 claims abstract description 18
- 230000000869 mutational effect Effects 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims description 62
- 230000035772 mutation Effects 0.000 claims description 41
- 238000001914 filtration Methods 0.000 claims description 36
- 238000004458 analytical method Methods 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000033607 mismatch repair Effects 0.000 claims description 20
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 19
- 102000043129 MHC class I family Human genes 0.000 claims description 17
- 108091054437 MHC class I family Proteins 0.000 claims description 17
- 230000005778 DNA damage Effects 0.000 claims description 14
- 231100000277 DNA damage Toxicity 0.000 claims description 14
- 102000043131 MHC class II family Human genes 0.000 claims description 13
- 108091054438 MHC class II family Proteins 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 11
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 10
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 10
- 108091092878 Microsatellite Proteins 0.000 claims description 9
- 230000002950 deficient Effects 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 238000009169 immunotherapy Methods 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 230000000391 smoking effect Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 4
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 108700019961 Neoplasm Genes Proteins 0.000 claims description 2
- 102000048850 Neoplasm Genes Human genes 0.000 claims description 2
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 claims 2
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 8
- 108020004707 nucleic acids Proteins 0.000 abstract description 7
- 102000039446 nucleic acids Human genes 0.000 abstract description 7
- 108700028369 Alleles Proteins 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 18
- 238000003559 RNA-seq method Methods 0.000 description 14
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 13
- 108010075704 HLA-A Antigens Proteins 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- 238000012070 whole genome sequencing analysis Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000000126 in silico method Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 8
- 102000054765 polymorphisms of proteins Human genes 0.000 description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 201000002510 thyroid cancer Diseases 0.000 description 6
- 208000033781 Thyroid carcinoma Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 5
- 201000003701 uterine corpus endometrial carcinoma Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000037432 silent mutation Effects 0.000 description 4
- 230000001360 synchronised effect Effects 0.000 description 4
- 102210048101 A*01:01 Human genes 0.000 description 3
- 102210047469 A*02:01 Human genes 0.000 description 3
- 102210042925 HLA-A*02:01 Human genes 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 101150013568 US16 gene Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010205 computational analysis Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000024312 invasive carcinoma Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002552 multiple reaction monitoring Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007482 whole exome sequencing Methods 0.000 description 3
- 102210042961 A*03:01 Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 102100033811 A-kinase anchor protein 11 Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- -1 DLBC Chemical compound 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 102100022116 F-box only protein 2 Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 101000779390 Homo sapiens A-kinase anchor protein 11 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000824158 Homo sapiens F-box only protein 2 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000636582 Homo sapiens N-alpha-acetyltransferase 50 Proteins 0.000 description 1
- 101001134896 Homo sapiens Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 Proteins 0.000 description 1
- 101000868154 Homo sapiens Son of sevenless homolog 2 Proteins 0.000 description 1
- 101000841466 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 8 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100031957 N-alpha-acetyltransferase 50 Human genes 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102100033431 Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 Human genes 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100032930 Son of sevenless homolog 2 Human genes 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 102100029088 Ubiquitin carboxyl-terminal hydrolase 8 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000013079 data visualisation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 231100000310 mutation rate increase Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000037438 passenger mutation Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102200119072 rs752513525 Human genes 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000007704 wet chemistry method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Primary Health Care (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240494P | 2015-10-12 | 2015-10-12 | |
| US62/240,494 | 2015-10-12 | ||
| PCT/US2016/056692 WO2017066357A1 (en) | 2015-10-12 | 2016-10-12 | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016339035A1 true AU2016339035A1 (en) | 2018-05-10 |
Family
ID=57882841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016339035A Abandoned AU2016339035A1 (en) | 2015-10-12 | 2016-10-12 | Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11626187B2 (enExample) |
| EP (1) | EP3362930A4 (enExample) |
| JP (1) | JP2018532736A (enExample) |
| KR (1) | KR20180087244A (enExample) |
| CN (1) | CN108701173A (enExample) |
| AU (1) | AU2016339035A1 (enExample) |
| CA (1) | CA3003251A1 (enExample) |
| HK (1) | HK1258091A1 (enExample) |
| IL (1) | IL258679A (enExample) |
| WO (1) | WO2017066357A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| JP2018532736A (ja) | 2015-10-12 | 2018-11-08 | ナントミクス，エルエルシー | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
| EP3414692A4 (en) | 2016-02-12 | 2020-07-29 | Nantomics, LLC | HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES |
| US11875877B2 (en) | 2016-08-25 | 2024-01-16 | Nantomics, Llc | Immunotherapy markers and uses therefor |
| IL268919B2 (en) * | 2017-03-03 | 2023-10-01 | Treos Bio Zrt | A personalized immunogenic peptide identification platform |
| CN111373050A (zh) * | 2017-06-20 | 2020-07-03 | 生物辐射实验室股份有限公司 | 用于遗传不稳定性的数字扩增试验 |
| WO2019031939A2 (ko) * | 2017-08-10 | 2019-02-14 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| US11773449B2 (en) | 2017-09-01 | 2023-10-03 | The Hospital For Sick Children | Profiling and treatment of hypermutant cancer |
| US20200385815A1 (en) * | 2017-12-20 | 2020-12-10 | Nantomics, Llc | Using cfRNA for Diagnosing Minimal Residual Disease |
| EP3784802A1 (en) * | 2018-04-25 | 2021-03-03 | Koninklijke Philips N.V. | Tumor functional mutation and epitope loads as improved predictive biomarkers for immunotherapy response |
| EP3826669A2 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| WO2020041561A1 (en) * | 2018-08-23 | 2020-02-27 | Nantcell, Inc. | Assessing microsatellite instability by liquid biopsy |
| JP7642530B2 (ja) | 2018-09-04 | 2025-03-10 | トレオス バイオ リミテッド | ペプチドワクチン |
| WO2020091944A1 (en) * | 2018-10-31 | 2020-05-07 | Nantomics, Llc | Genomic and immune infiltration differences between msi and mss gi tumors |
| CN110556164B (zh) * | 2019-09-09 | 2023-02-07 | 深圳裕策生物科技有限公司 | 用于目标区域捕获测序检测msi的方法、装置和存储介质 |
| CN110910957B (zh) * | 2019-12-31 | 2023-06-27 | 求臻医学科技(浙江)有限公司 | 一种基于单肿瘤样本高通量测序微卫星不稳定性探测位点筛选方法 |
| CN111785324B (zh) * | 2020-07-02 | 2021-02-02 | 深圳市海普洛斯生物科技有限公司 | 一种微卫星不稳定分析方法及装置 |
| CN112183557A (zh) * | 2020-09-29 | 2021-01-05 | 山西医科大学 | 基于胃癌组织病理图像纹理特征的msi预测模型构建方法 |
| CN114974420A (zh) * | 2021-10-29 | 2022-08-30 | 无锡臻和生物科技有限公司 | 预测胃肠肿瘤免疫检查点抑制剂疗效的标志物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1461001A4 (en) | 2002-01-03 | 2010-03-31 | Scripps Research Inst | ASSOCIATED WITH CANCER EPITOP |
| PL1601450T3 (pl) | 2003-03-10 | 2014-03-31 | Expression Pathology Inc | Ciekły preparat tkankowy z próbek biologicznych, tkanek i komórek poddanych obróbce histopatologicznej |
| WO2005019432A2 (en) | 2003-08-20 | 2005-03-03 | Cleveland Clinic Foundation Innovations | A novel gene and protein associated with angiogenesis and endothelial apoptosis |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| JP4852046B2 (ja) | 2004-10-12 | 2012-01-11 | クルセル ホランド ベー ヴェー | 癌の治療及び検出に用いる結合分子 |
| US7811993B2 (en) | 2005-06-29 | 2010-10-12 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
| US8906367B2 (en) | 2007-01-05 | 2014-12-09 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| KR102315754B1 (ko) | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
| KR102042253B1 (ko) | 2010-05-25 | 2019-11-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2013323368B2 (en) | 2012-09-28 | 2019-03-21 | The University Of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
| CA2908434C (en) | 2013-04-07 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| AU2014337063A1 (en) * | 2013-10-18 | 2016-05-19 | Adaptive Biotechnologies Corp. | Predicting patient responsiveness to immune checkpoint inhibitors |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| KR20160102314A (ko) | 2014-01-02 | 2016-08-29 | 메모리얼 슬로안-케터링 캔서 센터 | 면역 치료요법에 대한 암 반응의 결정인자 |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| RU2018106934A (ru) | 2015-08-25 | 2019-09-26 | Нантомикс, Ллс | Системы и способы высокоточного определения вариантов |
| JP2018532736A (ja) | 2015-10-12 | 2018-11-08 | ナントミクス，エルエルシー | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
-
2016
- 2016-10-12 JP JP2018519039A patent/JP2018532736A/ja active Pending
- 2016-10-12 HK HK19100475.3A patent/HK1258091A1/zh unknown
- 2016-10-12 CA CA3003251A patent/CA3003251A1/en active Pending
- 2016-10-12 CN CN201680065549.6A patent/CN108701173A/zh not_active Withdrawn
- 2016-10-12 US US15/292,021 patent/US11626187B2/en active Active
- 2016-10-12 EP EP16856134.8A patent/EP3362930A4/en not_active Withdrawn
- 2016-10-12 AU AU2016339035A patent/AU2016339035A1/en not_active Abandoned
- 2016-10-12 WO PCT/US2016/056692 patent/WO2017066357A1/en not_active Ceased
- 2016-10-12 KR KR1020187013060A patent/KR20180087244A/ko not_active Withdrawn
-
2018
- 2018-04-12 IL IL258679A patent/IL258679A/en unknown
-
2023
- 2023-02-02 US US18/163,664 patent/US20230307090A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3003251A1 (en) | 2017-04-20 |
| US11626187B2 (en) | 2023-04-11 |
| WO2017066357A1 (en) | 2017-04-20 |
| US20170032082A1 (en) | 2017-02-02 |
| HK1258091A1 (zh) | 2019-11-01 |
| EP3362930A4 (en) | 2019-06-19 |
| KR20180087244A (ko) | 2018-08-01 |
| CN108701173A (zh) | 2018-10-23 |
| US20230307090A1 (en) | 2023-09-28 |
| EP3362930A1 (en) | 2018-08-22 |
| JP2018532736A (ja) | 2018-11-08 |
| IL258679A (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230307090A1 (en) | Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors | |
| US20220270709A1 (en) | High-Throughput Identification of Patient-Specific Neoepitopes as Therapeutic Targets for Cancer Immunotherapies | |
| US20240079089A1 (en) | Immunotherapy Markers And Uses Therefor | |
| Litchfield et al. | Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition | |
| Hudecova et al. | Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA | |
| Radovich et al. | The integrated genomic landscape of thymic epithelial tumors | |
| Williams et al. | Multiple mechanisms of MYCN dysregulation in Wilms tumour | |
| Vos et al. | Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial | |
| CN110997943A (zh) | 评估癌症免疫疗法的适合性的方法 | |
| Wan et al. | Integrative Multi− Omics Analysis Reveals Candidate Biomarkers for Oral Squamous Cell Carcinoma | |
| Newell et al. | Plasma-derived cell-free mitochondrial DNA: A novel non-invasive methodology to identify mitochondrial DNA haplogroups in humans | |
| Guo et al. | Quantitative characterization of tumor cell-free DNA shortening | |
| Wu et al. | Quantification of neoantigen-mediated immunoediting in cancer evolution | |
| Heyliger et al. | Prognostic relevance of ZNF844 and Chr 19p13. 2 KRAB-Zinc finger proteins in clear cell renal carcinoma | |
| Sverchkova et al. | Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response | |
| Hoff et al. | Novel RNA variants in colorectal cancers | |
| US20220296642A1 (en) | Methods of Making Therapeutic T Lymphocytes | |
| CN118451200A (zh) | 用于从细胞游离dna推断基因表达和起源组织的系统和方法 | |
| Ye et al. | Liver failure diagnosis: key diagnostic biomarkers discovery and bioinformatic validation | |
| Hao | Statistical Issues in Epigenome-Wide Association Studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |